Thanks to generous donations ($17m) from Marc and Lynne Benioff (Salesforce) and Mark and Debra Leslie (Veritas), Stanford is now launching an initiative to harness the communities of microbes inhabiting the human body—known as the microbiome—to develop new therapies for debilitating diseases. Known as the Stanford Microbiome Therapies Initiative (MITI), it is a joint initiative with Stanford ChEM-H and the Department of Bioengineering.
The Stanford team seeks to develop and transform the microbiome to create new therapies that will be utilized in clinical trials. Microbiome science holds considerable promise for the advancement of new therapies to treat various diseases.
Michael Fischbach, Associate Professor of Bioengineering will lead MITI
Carolyn Bertozzi, Professor of Chemistry, Baker Family Co-Director of Stanford ChEM-H